semaglutide cardiovascular news lowers events even without major weight loss, researchers report Weight-loss drug tied to lower

Description

One of the concerns about GLP-1s has been the cost of people being on them long-term, she said

Population and endpoints A definitive trial would enroll patients with biopsy-confirmed MASH and clinically meaningful fibrosis typically stage F2F3, the range where progression risk and regulatory interest are highest and would be powered against the two histologic endpoints regulators recognize: resolution of steatohepatitis without worsening of fibrosis, and improvement in fibrosis by at least one stage without worsening of steatohepatitis

It has been approved in the European Union, Mexico, Australia, and Japan as a once-daily therapeutic (20 g) to be used in combination with basal insulin

Isn't it important to understand the nuances of these medications before making a decision

In addition, differences in study designranging from single-center cohorts to large databases, use of various GLP-1 agents, and diverse comparator strategiescontribute to the variability in outcomes